Kura Oncology, Inc.

KURA

US50127T1097

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:06:54 20/05/2024 BST			5-day change	1st Jan Change
22.42 ^USD	+1.15%		+8.64%	+55.70%

05-15	Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
05-14	Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug	MT

Kura Oncology, Inc. Announce Resignation of Robert E. Hoffman as Member of the Board of Directors

June 04, 2021 at 12:37 pm

On June 3, 2021, Robert E. Hoffman tendered his resignation as a member of the Board of Directors Kura Oncology, Inc. and all committees thereof, effective as of August 3, 2021.

Latest news about Kura Oncology, Inc.

Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	05-15
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug	05-14	MT
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML	05-14	CI
Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Sector Update: Health Care Stocks Advance Premarket Monday	04-22	MT
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	04-22	DJ
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	04-22	MT
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	04-22	CI
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM	03-14
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	03-06	CI
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024	02-27
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	02-26	CI
Kura Oncology Says Study of Leukemia Combination Therapy Yields Positive Early Data	01-30	MT
Transcript : Kura Oncology, Inc. - Special Call	01-30
Top Premarket Gainers	01-30	MT
Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia	01-30	CI
Kura Oncology, Inc. announced that it has received $150 million in funding from EcoR1 Capital, LLC	01-25	CI
Kura Oncology Expects to Raise $150 Million in Gross Proceeds From Oversubscribed Private Placement	01-24	MT
Top Premarket Gainers	01-24	MT
Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC	01-23	CI
Mizuho Securities Initiates Kura Oncology With Buy Rating, Price Target is $26	12-22	MT
Sector Update: Health Care Stocks Lean Lower Premarket Friday	12-08	MT

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.17 USD

Average target price

30.25 USD

Spread / Average Target

+36.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KURA ONCOLOGY, INC.	+55.70%	1.69B
VERTEX PHARMACEUTICALS INCORPORATED	+9.81%	115B
REGENERON PHARMACEUTICALS, INC.	+11.91%	106B
ARGENX SE	-2.50%	21.96B
BIONTECH SE	-13.80%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.39%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+6.41%	14.32B
SAREPTA THERAPEUTICS, INC.	+34.49%	12.42B

Bio Therapeutic Drugs